Current Clinical Trials
Our clinical trials aim to determine how drugs and other therapies can prevent or treat medical problems seen in individuals with NF1 and NF2.
Search for additional current clinical trials at clinicaltrials.gov »
Learn about the NF Clinical Trials Consortium at UAB »
Neurofibromatosis Type 1 (NF1) trials
General NF1 clinical trials
- Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1 (DoDNAC)
- Comparison of Gastrointestinal Motility in Healthy Children and Children With Constipation
- Frameshift Peptides of Children With NF1
- Immunotherapy Based on Antigen-specific Immune Effector Cells Targeting Neurofibromatosis or Schwannomatosis
- Medication Adherence in Children, Adolescents and Adults With Neurofibromatosis Type 1 (NF1) on Clinical Treatment Trials
- Natural History Study of Patients with Neurofibromatosis Type 1*
- Neurofibromatosis (NF) Registry Portal
- Resiliency Training in Adolescents With NF1 and NF2
- Resiliency Training for Adults With Neurofibromatosis Via Live Videoconferencing
Cutaneous neurofibroma trials
- Evaluating Genetic Modifiers of Cutaneous Neurofibromas in Adults With Neurofibromatosis Type 1
- HIFU Treatment of Cutaneous Neurofibromas in Neurofibromatosis Type 1: Safety and Efficacy*
- NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)
- Photodynamic Therapy for Benign Dermal Neurofibromas
- Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma*
Plexiform neurofibroma trials
- Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults (NF105-CABO)*
- Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (PNs)
- MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas (RENEU)*
- HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
- Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours
- MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas*
-
Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas (NF108-BINI)*
- PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)
- Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1
- Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.
- Treatment of NF1-related Plexiform Neurofibroma With Trametinib (plexifpc)*
Learning disabilities/attention deficit trials
- Intervention Effectiveness on the Neurocognitive Functioning of Children and Adolescents With Neurofibromatosis Type 1
- Interventions for Reading Disabilities in NF1
Malignant peripheral nerve sheath tumor (MPNST) trials
- A Clinical Trial to Evaluate the Safety and Efficacy of AL2846 Capsules in Chinese Patients With Type I Neurofibromatosis
- A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)
- A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients
- Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors
- Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor
- Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma
- PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors (PLX3397)
- SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors*
- Tazemetostat in Malignant Peripheral Nerve Sheath Tumors
- Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, CB-839 HCl, Anti-Cancer Treatment, BeGIN Study*
- Vaccine Therapy in Treating Patients With Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery
Brain tumor (glioma) trials
- Phase I/II Study of MEK162 for Children With Ras/Raf Pathway Activated Tumors*
- Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma*
- A Phase II Trial of Poly-ICLC for Low-Grade Gliomas
- A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma
- A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration
- Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG)
Other tumors/cancer trials
- Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas
- Diagnosis of Pheochromocytoma
- Familial Investigations of Childhood Cancer Predisposition (SJFAMILY)
- GIST: Assessment of Tumor Mutations and TKI Plasma Exposure
- Immunotherapy Based on Antigen-specific Immune Effector Cells Targeting Neurofibromatosis or Schwannomatosis
- NCI-MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma
- Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia
Neurofibromatosis Type 2 (NF2) trials
General NF2 clinical trials
- Cutaneous and Mucosal Manifestations of Neurofibromatosis Type 2 in Children Under 15
- Natural History Study of Patients With Neurofibromatosis Type 2
- Neurofibromatosis (NF) Registry Portal
- Resiliency Training in Adolescents With NF1 and NF2
- Resiliency Training for Adults With Neurofibromatosis Via Live Videoconferencing
- Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors
Schwannoma trials
- CI Following VS Removal or Labyrinthectomy
- Cochlear Implantation After Gamma Knife Radiosurgery With eABR and Correlation to Postoperative Hearing Results – a Pilot Study
- Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma
- Immunotherapy Based on Antigen-specific Immune Effector Cells Targeting Neurofibromatosis or Schwannomatosis
- Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas (NF110)*
- Simultaneous Cochlear Implantation During Translabyrinthine Resection of Vestibular Schwannoma*
- Simultaneous Translabyrinthine Surgery of Vestibular Schwannoma and Cochlear Implantation With Intraoperative eBERA and Correlation to Hearing Results
- Study of Aspirin in Patients With Vestibular Schwannoma
- Targeted Imaging of Glutamate Carboxypeptidase II With DCFPyL-PET
- Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors (SEL-TH-1601)
- Vestibular Outcomes in Vestibular Schwannoma (VOVS)*
- Use of DTT to Define Facial Nerve Position in Vestibular Schwannomas
Meningioma trials
- Carbon Ion Radiotherapy for Atypical Meningiomas (MARCIE)
- Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas (POPLAR-NF2)
- Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers
- Multisession Radiosurgery for Optic Nerve Sheath Meningiomas (ONSMsmSRS)*
- Neoadjuvant Avelumab and Hypofractionated Proton Radiation Therapy Followed by Surgery for Recurrent Radiation-refractory Meningioma*
- Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
- Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma*
- Predictive Factors of Visual Recovery After Paraoptic Tumors Removal (PRONOPTIC)
- A Study of Nivolumab in Adult Participants With Recurrent High-Grade Meningioma
- A Trial of Increased Dose Intensity Modulated Proton Therapy (IMPT) for High-Grade Meningiomas
- Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas*
*Studies that are active but not recruiting